Cargando…
An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV), first approved in 2017, has high, long-lasting efficacy against herpes zoster (HZ) and a clinically acceptable safety profile. In addition to the prevention of HZ in adults aged ≥50 years, the non-live RZV can be used from age 18 years in...
Autores principales: | Parikh, R, Widenmaier, R, Weller, R, Lecrenier, N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594798/ http://dx.doi.org/10.1093/eurpub/ckac129.728 |
Ejemplares similares
-
Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022) -
The impact of the COVID-19 pandemic on the incidence of herpes zoster: Nicolas Lecrenier
por: Lecrenier, N, et al.
Publicado: (2022) -
National vaccination program compliance in northern Lisbon's primary healthcare: 2022 assessment
por: Mateus da Costa, M, et al.
Publicado: (2023) -
Complex vaccination strategies prevent the emergence of vaccine resistance
por: Rella, S A, et al.
Publicado: (2023) -
Designing and planning natural experimental evaluations with good practice recommendations
por: Craig, P
Publicado: (2023)